A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Administered By

Awarded By

Contributors

Start/End

  • September 13, 2019 - September 14, 2024